Company: SPRB
Filing Date: 2025-10-08
Form Type: 8-K
Source: 0001193125-25-234516
Chunk: 1

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-10-08
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01      Other Events.  

The Company intends on advancing tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) through a biologics license application submission in the first quarter of 2026 and potential U. S. commercial launch in late 2026.

Forward-Looking Statements

This Current Report on Form8-Kcontains forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the offering, such as the expected gross proceeds and anticipated closing date, and the timing of BLA submission and potential commercial launch. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Quarterly Report on Form10-Qfor the fiscal quarter ended June 30, 2025 and in the Company’s other periodic and Current Reports filed with the SEC. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

  Item 9.01      Financial Statements and Exhibits.  

(d) Exhibits.

  Exhibit      Description                                                                                                              
                                                                                                                                        
   Number                                                                                                                               
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      4.1      Form of Pre-Funded Warrant to Purchase Common Stock